Current News

Contact | Print version | PDF version | Send article | RSS-Feed

Jerini expands collaboration with Baxter to develop non-intraveneous hemophilia therapy

07 Feb 2007 - Jerini AG announced the expansion of their current research collaboration with Baxter AG for the development of a non-intravenous therapy for the treatment of hemophilia. The companies have initiated two additional programs aimed at novel targets, potentially offering new therapeutic developments in the treatment of hemophilia. These new agreements, along with the existing collaboration, focus on three specific targets associated with the disease.
 
Under the terms of the expanded agreement, Jerini will receive upfront payments and full time equivalents (FTE) funding for each of the two new programs, with potential milestone payments for the achievement of discovery, preclinical, and clinical goals as well as royalties on eventual product sales. The original collaboration between Baxter and Jerini was initiated in 2001 and expanded in 2004.